deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04009473

Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation (SEGOVA)

Platelet Rich Plasma Ovarian in Vitro Activation and Stem Cells Transplantation In Women With Ovarian Failure

Sponsor: Forever Young d.o.o.

Conditions Menopause Menopause Ovarian Failure Menopause, Premature Ovarian Failure Ovarian Failure Secondary Ovarian Failure, Premature Ovarian Insufficiency Ovarian Insufficiency, Primary Premature Ovarian Failure Premature Ovarian Failure 1 Premature Ovarian Failure 10 Premature Ovarian Failure 11 Premature Ovarian Failure 12 Premature Ovarian Failure 13 Premature Ovarian Failure 14 Premature Ovarian Failure 2A Premature Ovarian Failure 2B Premature Ovarian Failure 3 Premature Ovarian Failure 4 Premature Ovarian Failure 5 Premature Ovarian Failure 6 Premature Ovarian Failure 7 Premature Ovarian Failure 8 Premature Ovarian Failure 9
Interventions SEGOVA procedure
Updated 7 times since 2019 Last updated: Aug 5, 2020 Started: Jun 1, 2019 Primary completion: Dec 31, 2020 Completion: Dec 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Menopause and Menopause Ovarian Failure and is currently ongoing. Forever Young d.o.o. leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshotEnrolling By Invitation~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshotEnrolling By Invitation~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotEnrolling By Invitation~Jan 2021 – ~Nov 2022 · 22 months · monthly snapshotEnrolling By Invitation~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 23 months · monthly snapshotUnknown

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Nov 2022 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Enrolling By Invitation → Unknown Status

  4. Jan 2021 — Nov 2022 [monthly]

    Enrolling By Invitation PHASE1_PHASE2

  5. Sep 2020 — Jan 2021 [monthly]

    Enrolling By Invitation PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Mar 2020 — Sep 2020 [monthly]

    Enrolling By Invitation PHASE1_PHASE2

  2. Aug 2019 — Mar 2020 [monthly]

    Enrolling By Invitation PHASE1_PHASE2

    First recorded

Jun 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Forever Young d.o.o.
  • Medigroup Health System, Jevremova hospital
  • Re-medika Hospital Skoplje
  • Saint James Hospital Malta
Data source: Forever Young d.o.o.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations